Bristol-Myers Squibb releases Onglyza study results

Bristol-Myers Squibb has released the results of a clinical study into the type 2 diabetes mellitus drug Onglyza (saxagliptin), which it has been developing in conjunction with AstraZeneca.

The 18-week phase III trial found that a combination of metformin therapy and Onglyza doses of 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with Januvia (sitagliptin) 100 mg per day in reducing HbA1c from baseline.

Andre Scheen, head of the division of diabetes, nutrition and metabolic disorders at the Academic Hospital of Liege, stated: “We are pleased with the findings from this study, which support that the addition of Onglyza to metformin lowers HbA1c in adults with inadequate glycemic control despite treatment with metformin.”

This news comes after Bristol-Myers Squibb announced that it is to present data on its products Baraclude (entecavir), BMS-650032, lambda and brivanab at the 60th annual meeting of the American Association for the Study of Liver Diseases later this month.